Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J G Meingassner

Showing results (31-40 of 44) with videos related to

Pageof 5
Sort By:
Journal of Medical and Veterinary Mycology : Bi-Monthly Publication of the International Society for Human and Animal Mycology|January 1, 1990
Preclinical antimycotic activity of SDZ 89-485: a new orally and topically effective triazoleM Schaude, G Petranyi, H Ackerbauer, et al.
American Journal of Obstetrics and Gynecology|December 1, 1980
Three metronidazole-resistant strains of Trichomonas vaginalis from the United StatesM Müller, J G Meingassner, W A Miller, et al.
The British Journal of Dermatology|November 18, 2003
Pimecrolimus does not affect Langerhans cells in murine epidermisJ G Meingassner, E Kowalsky, H Schwendinger, et al.
Antimicrobial Agents and Chemotherapy|January 1, 1978
Assay conditions and the demonstration of nitroimidazole resistance in Tritrichomonas foetusJ G Meingassner, H Mieth, R Czok, et al.
Journal of Medicinal Chemistry|June 24, 1994
Derivatives of a novel cyclopeptolide. 1. Synthesis, antifungal activity, and structure-activity relationshipsG Emmer, M A Grassberger, J G Meingassner, et al.
The Journal of Investigative Dermatology|July 17, 1998
MDP(Lysyl)GDP, a nontoxic muramyl dipeptide derivative, inhibits cytokine production by activated macrophages and protects mice from phorbol ester- and oxazolone-induced inflammationM Zunic, G M Bahr, G C Mudde, et al.
Journal of Dermatological Science|June 30, 2006
Pimecrolimus and tacrolimus differ in their inhibition of lymphocyte activation during the sensitization phase of contact hypersensitivityA Bavandi, H Fahrngruber, H Aschauer, et al.
The British Journal of Dermatology|December 9, 1997
A novel anti-inflammatory drug, SDZ ASM 981, for the topical and oral treatment of skin diseases: in vivo pharmacologyJ G Meingassner, M Grassberger, H Fahrngruber, et al.
Archives of Dermatological Research|November 10, 1998
Ascomycin macrolactam derivative SDZ ASM 981 inhibits the release of granule-associated mediators and of newly synthesized cytokines in RBL 2H3 mast cells in an immunophilin-dependent mannerT Hultsch, K D Müller, J G Meingassner, et al.
Journal of Medicinal Chemistry|July 23, 1993
Synthesis and structure-activity relationships of phenyl-substituted benzylamine antimycotics: a novel benzylbenzylamine antifungal agent for systemic treatmentP Nussbaumer, G Dorfstätter, M A Grassberger, et al.
Pageof 5

Showing results (31-40 of 44) with videos related to

Sort By:
Pageof 5
Journal of Medical and Veterinary Mycology : Bi-Monthly Publication of the International Society for Human and Animal Mycology|January 1, 1990
Preclinical antimycotic activity of SDZ 89-485: a new orally and topically effective triazoleM Schaude, G Petranyi, H Ackerbauer, et al.
American Journal of Obstetrics and Gynecology|December 1, 1980
Three metronidazole-resistant strains of Trichomonas vaginalis from the United StatesM Müller, J G Meingassner, W A Miller, et al.
The British Journal of Dermatology|November 18, 2003
Pimecrolimus does not affect Langerhans cells in murine epidermisJ G Meingassner, E Kowalsky, H Schwendinger, et al.
Antimicrobial Agents and Chemotherapy|January 1, 1978
Assay conditions and the demonstration of nitroimidazole resistance in Tritrichomonas foetusJ G Meingassner, H Mieth, R Czok, et al.
Journal of Medicinal Chemistry|June 24, 1994
Derivatives of a novel cyclopeptolide. 1. Synthesis, antifungal activity, and structure-activity relationshipsG Emmer, M A Grassberger, J G Meingassner, et al.
The Journal of Investigative Dermatology|July 17, 1998
MDP(Lysyl)GDP, a nontoxic muramyl dipeptide derivative, inhibits cytokine production by activated macrophages and protects mice from phorbol ester- and oxazolone-induced inflammationM Zunic, G M Bahr, G C Mudde, et al.
Journal of Dermatological Science|June 30, 2006
Pimecrolimus and tacrolimus differ in their inhibition of lymphocyte activation during the sensitization phase of contact hypersensitivityA Bavandi, H Fahrngruber, H Aschauer, et al.
The British Journal of Dermatology|December 9, 1997
A novel anti-inflammatory drug, SDZ ASM 981, for the topical and oral treatment of skin diseases: in vivo pharmacologyJ G Meingassner, M Grassberger, H Fahrngruber, et al.
Archives of Dermatological Research|November 10, 1998
Ascomycin macrolactam derivative SDZ ASM 981 inhibits the release of granule-associated mediators and of newly synthesized cytokines in RBL 2H3 mast cells in an immunophilin-dependent mannerT Hultsch, K D Müller, J G Meingassner, et al.
Journal of Medicinal Chemistry|July 23, 1993
Synthesis and structure-activity relationships of phenyl-substituted benzylamine antimycotics: a novel benzylbenzylamine antifungal agent for systemic treatmentP Nussbaumer, G Dorfstätter, M A Grassberger, et al.
Pageof 5